Maravai LifeSciences Holdings Inc (NASDAQ: MRVI) Stock Declined -3.66% Last Week – That’s Proof That Its Volatility Isn’t Going Anywhere

Maravai LifeSciences Holdings Inc (NASDAQ:MRVI) does about 2.19M shares in volume on a normal day but saw 1702996 shares change hands in Monday trading. The company now has a market cap of 1.12B USD. Its current market price is $8.43, marking a decrease of -2.09% compared to the previous close of $8.61. The 52 week high reached by this stock is $14.88 whilst the lowest price level in 52 weeks is $4.52.

Maravai LifeSciences Holdings Inc (MRVI) has a 20-day trading average at $9.93 and the current price is -43.35% off the 52-week high compared with 86.50% distance from its 52-week low. The 50-day simple moving average of the closing price is $8.98 and its 200-day simple moving average is $7.67. If we look at the stock’s price movements over the week, volatility stands at 3.72%, which increases to 4.89% over 1 month. It is also key to look at other market indicators of price movement for the stock, where we see that the relative strength index (RSI) is at 36.41 to suggest the stock is neutral.

The consensus objective for the share price is $10.85, suggesting that the stock has a potential upside of 22.3% over the period.

The company shares received a number of brokerage firm price updates over the past month, with the latest being on April 10, 2024 when Craig Hallum initiated the stock to “Buy” and issued a price target of $15. BofA Securities upgraded the stock to “Buy” from Neutral on December 12, 2023 at a price target of $10-$8.

Maravai LifeSciences Holdings Inc (MRVI) stock is down -3.66% over the week and -14.50% over the past month. Its price is 28.70% year-to-date and -37.60% over the past year.

The stock last released its quarterly earnings report for quarter ended 3/31/2024, with the company’s earnings per share (EPS) of 0 below consensus estimates by -0.01. The company’s next earnings report forecasts estimating quarterly EPS at 0.0 and -0.01 for whole year. Expected sales for next quarter are $68.06M, which analysts say will come at $275.22M for the current fiscal year and next year at $301.58M. In addition, estimates put the company’s current quarterly revenue at an average of $71.63M.

To reach the target analysts have set, the stock logically needs to grow 22.3 percent from here.

The company has a return on investment of -13.65% and return on equity of -28.11%. The forward price to earnings ratio is 184.63. The beta has a value of 0.06. Price to book ratio is 2.72 and price to sales ratio is 4.09.